Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung
cancer (NSCLC). Bevacizumab, a humanized monoclonal antibody against vascular endothelial
growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of
pleural fluid. The other widely used treatment for MPE is recombinant human endostatin.